Eveline Barbieri

Children's Cancer Center — United States

Medicine · Health Sciences

17h-index1.1kcitations113works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(100), Cancer, Hypoxia, and Metabolism(28), Protein Degradation and Inhibitors(24), Cancer-related Molecular Pathways(10), Glioma Diagnosis and Treatment(9)

Publications113 total

Deciphering the MYCN-driven metabolic microenvironment of neuroblastoma
Trends in Molecular Medicine·2025Open Access
Systematic Targeting of GD2‐Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector Platform
Advanced Science·2025· 2 citedOpen Access
Characterization of Persister Cells Provides Insights into Mechanisms of Therapy Resistance in Neuroblastoma
Cancer Discovery·2024· 5 cited
Reactivation of the G1 enhancer landscape underlies core circuitry addiction to SWI/SNF
Nucleic Acids Research·2023· 14 citedOpen Access
Supplementary Figure 3 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 4 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 4 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 6 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Data from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 7 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 8 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 7 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Data from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Information from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 8 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 6 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 1 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 5 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 5 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
Supplementary Figure 2 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Jason M. Shohet(32), Zaowen Chen(22), Eugene S. Kim(20), Myrthala Moreno‐Smith(15), Frank Speleman(12), Sanjeev A. Vasudevan(12), Anna Lakoma(11), Danielle M. Hsu(10), Cristian Coarfa(9), Katleen De Preter(9), Mario Capasso(8), Pieter Mestdagh(7), Andrea Pession(7), Alan Van Goethem(7), Jo Vandesompele(7), Ashley Benham(6), Preethi H. Gunaratne(6), Denae N. Trahan(6), Ling Tao(6), Paris N. Stowers(6)